Larimar Therapeutics (LRMR) EBITDA (2013 - 2026)

Larimar Therapeutics (LRMR) has reported EBITDA for 14 consecutive years, with -$34.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 23.6% year-over-year to -$34.4 million; the trailing twelve-month figure through Jun 2026 stood at -$175.7 million (down 61.84% YoY), and the FY2025 full-year result was -$172.5 million, down 89.79% from the prior year.
• EBITDA grew to -$34.4 million in Q2 2026 per LRMR's latest filing, from -$64.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$7.6 million in Q1 2023 and bottomed at -$64.0 million in Q4 2025.
• Historically, EBITDA has averaged -$22.1 million across 5 years, with a median of -$16.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: EBITDA jumped 49.12% in 2022, then plunged 171.02% in 2025.
• Over 5 years, EBITDA stood at -$10.4 million in 2022, then plunged by 35.66% to -$14.2 million in 2023, then plunged by 120.96% to -$31.3 million in 2024, then tumbled by 104.58% to -$64.0 million in 2025, then jumped by 46.34% to -$34.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$34.4 million, -$64.0 million, and -$49.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.